Biote Corp's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 83/156 in the Professional & Commercial Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.09.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biote Corp's Score
Industry at a Glance
Industry Ranking
83 / 156
Overall Ranking
218 / 4582
Industry
Professional & Commercial Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
5
analysts
Buy
Current Rating
5.093
Target Price
+98.96%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biote Corp Highlights
StrengthsRisks
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.
Fairly Valued
The company’s latest PE is 3.07, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.37M shares, decreasing 0.13% quarter-over-quarter.
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Ticker SymbolBTMD
CompanyBiote Corp
CEOChristensen (Bret)
Websitehttps://haymakeracquisition.com/
FAQs
What is the current price of Biote Corp (BTMD)?
The current price of Biote Corp (BTMD) is 2.780.
What is the symbol of Biote Corp?
The ticker symbol of Biote Corp is BTMD.
What is the 52-week high of Biote Corp?
The 52-week high of Biote Corp is 6.360.
What is the 52-week low of Biote Corp?
The 52-week low of Biote Corp is 2.315.
What is the market capitalization of Biote Corp?
The market capitalization of Biote Corp is 85.29M.
What is the net income of Biote Corp?
The net income of Biote Corp is 3.16M.
Is Biote Corp (BTMD) currently rated as Buy, Hold, or Sell?
According to analysts, Biote Corp (BTMD) has an overall rating of Buy, with a price target of 5.093.
What is the Earnings Per Share (EPS TTM) of Biote Corp (BTMD)?
The Earnings Per Share (EPS TTM) of Biote Corp (BTMD) is 0.906.